Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma
Status:
Not yet recruiting
Trial end date:
2029-01-08
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine how effective and safe the combination of
glofitamab and obinutuzumab is in treating patients with Follicular Lymphoma (FL) and
Marginal Zone Lymphoma (MZL) who have not received other treatments for their lymphoma.
The names of the study drugs involved in this study are:
- Glofitamab (a type of immunotherapy)
- Obinutuzumab (a type of immunotherapy)